|By Business Wire||
|March 12, 2014 02:45 AM EDT||
MEDIAN Technologies (Paris:ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced it has signed a contract with a global top five pharmaceutical company. Within the framework of this contract, MEDIAN will provide imaging services in a large phase I/II clinical trial. The contract amount is approximately €700K (eq. $ 960,000).
“We are very enthusiastic about this new contract with this global pharma company,” said Fredrik Brag, Chairman and Chief Executive Officer of MEDIAN Technologies. “This company is one of our historical clients, and this new contract is a clear demonstration of the confidence our client has in our innovative imaging services. As one of the top five pharmaceutical companies, this sponsor has a strategic focus and a large pipeline of upcoming studies in the oncology therapeutic area,” he added.
Within the framework of this clinical trial, imaging data will be acquired from clinical sites based in the US and Asia. Anticipated total enrollment is approximately 300 patients. MEDIAN will supply all imaging services requested for the study. Imaging services will be based on MEDIAN’s Lesion Management Solutions (LMS). LMS is a comprehensive suite of software modules for the review of images and quantitative assessment of response to therapy in clinical trials. MEDIAN’s LMS provides sponsors with very accurate and reliable imaging data.
This new contract is the second one signed by MEDIAN Technologies since the beginning of the year, for a total amount of more than 1M€. On January 29, MEDIAN Technologies also announced a project award for an amount of €639K.
About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).
For more information on MEDIAN, please visit: www.mediantechnologies.com
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”
Dec. 7, 2016 05:15 AM EST Reads: 1,040
Dec. 7, 2016 04:00 AM EST Reads: 855
Dec. 7, 2016 02:00 AM EST Reads: 615
Dec. 7, 2016 01:45 AM EST Reads: 6,160
Dec. 7, 2016 01:15 AM EST Reads: 1,872
Dec. 7, 2016 01:00 AM EST Reads: 1,614
Dec. 7, 2016 12:45 AM EST Reads: 3,933
Dec. 7, 2016 12:45 AM EST Reads: 1,238
Dec. 7, 2016 12:15 AM EST Reads: 1,371
Dec. 7, 2016 12:15 AM EST Reads: 1,024
Dec. 7, 2016 12:00 AM EST Reads: 1,267
Dec. 7, 2016 12:00 AM EST Reads: 2,125
Dec. 6, 2016 11:45 PM EST Reads: 745
Dec. 6, 2016 10:15 PM EST Reads: 1,151
Dec. 6, 2016 09:15 PM EST Reads: 349